Navigation Links
Octapharma Adopts Genedata Bioprocess to Develop Next-generation Bio-manufacturing Processes
Date:10/29/2019

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Octapharma, one of the world’s largest human protein manufacturers, has adopted the Genedata Bioprocess® platform to support the development and manufacturing of therapeutic proteins addressing severe diseases in the areas of haematology, immunotherapy, and critical care.

“By bringing Genedata Bioprocess onboard, we will be able to digitalize our development and manufacturing processes and get to the next level of operational excellence. Streamlining processes while maintaining highest quality standards was the guiding principle behind our selection of Genedata,” said Dr. Tobias Stuwe, Head of Recombinant R&D at Octapharma. “As a fully integrated end-to-end platform, Genedata Bioprocess integrates data capture, analysis, and reporting across all of our bioprocess development operations, which will increase overall productivity. In addition to these operational benefits, Genedata Bioprocess serves as our central data backbone to ensure data integrity and compliance.”

The system is being rolled out across the Octapharma organization, including groups for clinical supply and formulation development, purification and analytics, biophysics, fermentation, cell line development, molecular design, as well as Octapharma’s production and QC units in a GMP environment. All groups will have a central place to record and access business-critical information in real time, which will foster collaboration and ultimately help to make Octapharma’s development and manufacturing operations even more efficient.

E2E Platform for Bioprocess Development & CMC
Genedata Bioprocess is the leading biopharma R&D workflow platform, integrating processes and connecting people, data, and laboratory instruments to make corporate-wide development and manufacturing operations more efficient. The platform scales with highest data volumes and integrates all critical data, such as from bioreactors, downstream unit operations, or analytics devices. By harmonizing workflows, streamlining communications, giving real-time access to all project information, and enabling full automation and high-throughput processes, the platform reduces costs and dramatically improves overall productivity. Genedata Bioprocess supports the entire end-to-end (E2E) process, covering cell line development (CLD), upstream process development (USP), downstream process development (DSP), formulation development (FD), process analytical support, and analytical development (AD).

“We are pleased that Octapharma, a leader in therapeutic protein manufacturing, has decided to implement Genedata Bioprocess to handle the many challenges in large-molecule development and manufacturing,” said Dr. Othmar Pfannes, CEO of Genedata. “We are excited to combine Genedata’s advanced software solutions and expertise with Octapharma’s market-leading human protein development and production, which will further support our mutual goals of advancing human life.”

About Octapharma
Family-owned since being established in 1983, Octapharma is a global healthcare company headquartered in Lachen, Switzerland. Our products are available in 115 countries and reach hundreds of thousands of patients every year focussing on three therapeutic areas: haematology, immunotherapy and critical care.

Octapharma is one of the largest human protein product manufacturers. We develop and produce medicines based on human proteins from human cell lines and human plasma, sourced from our own plasma donation centres and other external sources.

About Genedata
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.

http://www.genedata.com
Follow Us on LinkedIn

Contact
Miles Fisher-Pollard
Genedata
Public Relations
Phone: +41 61 511 85 61
pr@genedata.com

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Read the full story at https://www.prweb.com/releases/octapharma_adopts_genedata_bioprocess_to_develop_next_generation_bio_manufacturing_processes/prweb16678197.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. EPSRC adopts 2 new Centres for Doctoral Training
2. Far north at risk unless Ontario adopts new, inclusive planning process: Report
3. Genedata Announces Aptevo Therapeutics Deploys Genedata Biologics to Streamline Cancer Immunotherapy R&D
4. Deep Learning-Based Genedata Imagence® for Automated High-Content Image Analysis Debuts at SLAS Conference
5. Genedata Licenses its Bioprocess Software Platform to Sartorius Stedim Cellca
6. Innovative solutions for lab-automation developed by Bioprocess Engineers from Dresden
7. Spectra Automation Introduces RECONN Bioprocess Manager
8. Sue Behrens Appointed to Lead KGI Bioprocessing Programs
9. Developmental neurobiology: How the brain folds to fit
10. Turtle genome analysis sheds light on the development and evolution of turtle-specific body plan
11. Study opens new prospects for developing new targeted therapies for breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2019)... ... , ... The MyOnyx rehab solution by Thought ... measure and display muscle activity in real time. This information helps the physical ... patient and therapist can see when exercises are performed correctly and efficiently. , ...
(Date:11/19/2019)... ... 19, 2019 , ... The inaugural Cell & Gene Therapy Day takes place ... one-day event will be chaired by Dr Aiman Shalabi, VP R&D, Cell and Gene ... “We are witnessing significant innovation in cell and gene therapies, and we are at ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... in the design and manufacturer of technical ergonomic seating solutions, announced this ... compliant with Healthier Hospital Initiative guidelines. Established by Practice Greenhealth, a health ...
Breaking Biology News(10 mins):
(Date:12/4/2019)... ... December 04, 2019 , ... Improved Pharma’s analytical methods ... materials. Additionally, their PDF Synchrotron methods provide a way to determine the structure ... in regulatory and patent applications.  , The latest developments were recently shared at ...
(Date:11/22/2019)... , ... November 22, 2019 ... ... engineering firm, hosted a live webinar covering a step-by-step cold chain validation ... antibody-drug conjugates, and cell therapies. Targeting complex cold chain biopharmaceutical industry leaders, ...
(Date:11/12/2019)... ... November 12, 2019 , ... REPROCELL Inc. a ... selected by Lantern Pharma to provided preclinical screening and drug sensitivity for its ... points using panels of unique and genetically edited cell lines from various tumors. ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... to educate Americans about the deadly healthcare-associated infection C. diff. The campaign, ... of the epidemic, which kills at least 30,000 people in the U.S. each ...
Breaking Biology Technology: